Study Links Periodontal Disease to Coronary Artery Disease
Researchers at the Department of Periodontology-Dental Surgery at
the University of Liege in Belgium report that 91% of the patients
they studied with cardiovascular disease suffered from moderate to
severe periodontitis. Periodontal disease seems to influence the
occurrence and severity of coronary artery disease and increases the
risk of heart attack or stroke. The study is published in the
Journal of Periodontology and is reported on Medline Plus, a
service of the National Institutes of health.
Phyllanthus Amarus Inhibits Drug Resistant HIV Virus
When drugs stop working on the HIV virus it is usually due to a
mutation of the virus leading to drug resistance. If the drugs fail
to work due to viral drug resistance the virus is free to replicate
and worsening infection can occur. In previous studies the herb
Phyllanthus Amarus (PA) inhibited HIV viral strains resistant to
reverse transcriptase inhibiting drugs. In this study PA blocked
the replication of HIV in a number of ways. It blocked the ability
of the HIV-1 virus from attaching to its primary receptor on the
CD4 immune cells. The PA also blocked a cross section of enzymes
that the virus needs to survive, multiply, and flourish: the integrase
enzyme, reverse transcriptase enzyme, and the protease enzyme. The
PA was administered to HIV positive volunteers to check the relevance
of this ability in patients and it was shown that the PA had a
potent HIV activity in the volunteer's blood. HIV replication was
inhibited by more than 30%. The study is published in the November
2004 issue of the journal Antiviral Research.
Phyllanthus Niruri Reduces the Risk of kidney Stone Formation
Phyllanthus Niruri (PN) is an herb used for many years in South
America to treat urinary calculi, the nucleus of most kidney stones.
In this study the researchers assessed the effects of PN
supplementation in calcium stone forming (CSF) patients. A total
of 69 CSF patients, both male and female were given either 450mg
of PN or placebo for 3 months. In patients who have high levels
of calcium sediment in the urine, the PN caused a significant
reduction in urinary calcium sediment. The study is published in
the October 2004 issue of the journal Urological Research.
Phyllanthus Amarus Protects Mice against Radiation and Reverses Damage
In this study, adult mice were given an extract of Phyllanthus
Amarus (PA) orally for 5 days before and for one month after full
body radiation exposure. The animals were sacrificed on days 3, 9,
12, and 30 after the radiation exposure. The PA significantly
improved the white blood cell count, improved the function of the
bone marrow, and improved enzyme levels needed for cellular protection
versus mice not protected with PA. PA increased levels pf protective
antioxidant enzymes including SOD, Catalase, and Glutathione related
enzymes both in the blood and tissues which were previously reduced
by radiation exposure. The activity of lipid peroxides increased
after radiation exposure, these peroxides cause inflammation and free
radical damage. PA greatly reduced the levels of the lipid peroxides,
both in the serum and the liver. The study is published in the March
2004 issue of the Journal of Radiation Research.
The Bone Building Drug Evista Decreases the Risk of Breast Cancer
Researchers studied 7,000 plus postmenopausal women with osteoporosis.
Over 5,000 were prescribed Evista and the rest received inactive
placebo. Evista decreased the risk of developing invasive breast
cancer by about 67% regardless if the woman was previously using
hormone replacement therapy or not. The study was presented at the
29th Annual Meeting of the European Society for Medical Oncology
held in Vienna, Austria October 29th through November 2nd 2004.
Commentary by Jerry Hickey, R.Ph.
Evista helps protect and build bone, it is a smart estrogen, and
lacks the carcinogenic effects of both Equine Conjugated Estrogens
and Tamoxifen. However, it still has a small risk of causing blood
clots (usually in the legs) but no where near Tamoxifen's level of
blood clot risk.